1. Home
  2. CNOBP vs CMMB Comparison

CNOBP vs CMMB Comparison

Compare CNOBP & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ConnectOne Bancorp Inc.

CNOBP

ConnectOne Bancorp Inc.

N/A

Current Price

$24.18

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

N/A

Current Price

$1.95

Market Cap

13.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNOBP
CMMB
Founded
N/A
2004
Country
United States
Israel
Employees
493
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
13.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CNOBP
CMMB
Price
$24.18
$1.95
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$26.50
AVG Volume (30 Days)
N/A
95.6K
Earning Date
N/A
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$1.73
52 Week High
N/A
$9.84

Technical Indicators

Market Signals
Indicator
CNOBP
CMMB
Relative Strength Index (RSI) 54.08 32.11
Support Level $24.16 $1.73
Resistance Level $24.25 $2.21
Average True Range (ATR) 0.10 0.25
MACD 0.00 -0.04
Stochastic Oscillator 70.87 23.07

Price Performance

Historical Comparison
CNOBP
CMMB

About CNOBP ConnectOne Bancorp Inc.

ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Share on Social Networks: